Beals John M, Shanafelt Armen B
Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Drug Discov Today Technol. 2006 Spring;3(1):87-94. doi: 10.1016/j.ddtec.2006.03.001.
Therapeutic proteins have made a major impact on medicine, with significant expansion in the past two decades. The medicinal attributes of these agents, particularly their efficacy and often their safety profile, make protein therapeutics attractive, despite the general necessity of invasive (parenteral) delivery. This perceived hurdle has been a primary component in limiting expansion of this class of drug therapies. Strategies that reduce the frequency of administration directly provide greater convenience to the patient, and potentially greater efficacy, that can yield a significant treatment advantage.:
治疗性蛋白质对医学产生了重大影响,在过去二十年中得到了显著发展。尽管这类药物通常需要侵入性(肠胃外)给药,但这些药物的药用特性,特别是它们的疗效以及通常的安全性,使得蛋白质疗法颇具吸引力。这种可感知的障碍一直是限制这类药物疗法扩展的主要因素。直接减少给药频率的策略能为患者带来更大的便利,并可能提高疗效,从而产生显著的治疗优势。